Christopher Mikson, MD, JD

Christopher Mikson, MD, JD, is a partner in Mayer Brown's Washington, DC office, where he serves as leader of the firm’s FDA Regulatory practice and coleader of the healthcare practice. He focuses his practice on FDA regulatory matters and complex litigation and transactional matters in healthcare and the life sciences.
Encouraging increased competition in the biologics market with biosimilars remains the most promising mechanism to increase access. One way to foster this goal is to equip our physicians with the tools they need to make the most informed, evidence-based clinical decisions possible for their patients, including on the issue of biosimilars.
Oct 14, 2019 @01:48 PM

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.